Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rosemary tea shows promise for mild high blood pressure

NCT ID NCT07386210

Disease control Sponsor: awatef Sassi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether drinking rosemary tea for 45 days can lower blood pressure in men with mild hypertension. Fifty-four men participated, with half drinking rosemary tea and half a placebo. The researchers measured blood pressure and checked how rosemary affects a key enzyme involved in blood pressure regulation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

54 people

The number who actually took part.

Started

Mar 2023

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male participants aged 28-65 years * Mild hypertension, defined as systolic blood pressure (SBP) 140-159 mmHg and/or diastolic blood pressure (DBP) 90-99 mmHg, according to ESC/ESH 2018 guidelines * No history of chronic diseases * Not currently taking antihypertensive medications, other drugs, or dietary supplements * Body mass index (BMI) within the screening range at recruitment * Provided written informed consent Exclusion Criteria: * Secondary hypertension * History of cardiovascular disease, diabetes mellitus, renal failure, autoimmune disease, or major gastrointestinal disorders * Current use of medications affecting blood pressure * Extreme body mass index (BMI) values * Significant dietary changes or irregular physical activity in the previous six months * Alcohol consumption or use of illicit drugs * Inability or unwillingness to maintain usual diet and lifestyle during the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension arterial are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign essential hypertension essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension arterial

Contacts and locations

Locations

  • Faculty of Medicine of Sousse

    Sousse, 4023, Tunisia

  • Sassi

    Sousse, Tunisia

More trials for these conditions

Other studies related to the condition(s) this trial covers.